

Jeffrey Dunn, MD, FAAN  
Stanford Neuroscience Health Center  
213 Quarry Road, Palo Alto, California 94304  
Work: 650 736-4310; Fax: 650 725-7459  
[jeffdunn@stanford.edu](mailto:jeffdunn@stanford.edu)  
2022

### **Academic Appointments:**

2022-present Lily Sarafan Director of Neuroimmunology,  
Neurology & Neurological Sciences, Stanford University; Stanford, CA  
2013-present Clinical Professor of Neurology,  
Neurology & Neurological Sciences; Stanford University; Stanford, CA  
2008-2012 Clinical Associate Professor of Neurology,  
Neurology and Neurological Sciences; Stanford University; Stanford, CA  
1997-2007 Clinical Assistant Professor of Neurology,  
Department of Neurology; University of Washington; Seattle, WA  
1993-1996 Clinical Instructor in Neurology,  
Medicine (Neurology); University of Washington; Seattle, WA  
1992-1993 Chief Resident in Neurology,  
Medicine (Neurology); University of Washington; Seattle, WA

### **Education:**

1985-1989 Doctor of Medicine (M.D.),  
Temple University School of Medicine; Philadelphia, PA  
1984-1985 Research Associate in Molecular Immunology;  
Fox Chase Cancer Center; Philadelphia, PA  
1979-1983 Bachelor of Arts (B.A.), French Literature  
Haverford College; Haverford, PA  
1982 Institut d'Études Françaises; Avignon, France

### **Postgraduate Training:**

1990-1993 Residency in Neurology  
University of Washington; Seattle, WA  
1989-1990 Internship in Medicine;  
Eastern Virginia Graduate School of Medicine; Norfolk, VA

### **Licensure and Certification:**

2016-present Diplomate recertification; with maintenance of certification MOC requirement;

American Board of Psychiatry & Neurology #40439: [www.abpn.com/verifycert](http://www.abpn.com/verifycert)  
 2004-2016 Diplomate recertification; American Board of Psychiatry & Neurology; # 40439  
 1994-2004 Diplomate, American Board of Psychiatry & Neurology; # 40439  
 1990 Diplomate, National Board of Medical Examiners; # 379589  
 2007-2021 Physician and Surgeon, California State; License # G88167  
 1993-2008 Physician and Surgeon, Washington State; License # 28894  
 1992-2024 DEA Registration, Schedules 2, 2N, 3, 3N, 4, 5; # BD285276  
 2005-present NIH Certified Principal Investigator for Research in Human Subjects  
 2016-present HIPAA Privacy for Clinical Researchers Certificate; LawRoom # 2349604  
 2013-2022 CITI Collaborative Institutional training Initiative; Stanford University  
 Human Subjects Research Protections Curriculum Completion Ref #18928151  
 Group 7: IRB BioMed/GCP Research refresher course certification: 9/19-9/22  
 2009-present Medical Research Investigators Certification; Stanford University  
 CITI Collaborative Institutional Training Initiative; # 1111159

### **Clinical Teaching Responsibilities:**

2008-2019 Neurology Clerkship Director  
 Department of Neurology and Neurosciences; Stanford University; Stanford, CA  
 2011-2017 Fellowship Director, Clinical Neuroimmunology  
 Department of Neurology and Neurosciences; Stanford University; Stanford, CA  
 2016-2018 Course Director, Annual Breakthroughs in Neurologic Therapies; San Francisco, CA  
 2008-2016 Ward and Consult Attending  
 Stanford University Hospital and Clinics; Stanford, CA  
 2008-2012 Preceptor, Neurology Residents' Clinic  
 Stanford University Hospital and Clinics; Stanford, CA  
 2004-2008 Preceptor, Multiple Sclerosis Fellowship  
 University of Washington: MS Hub and Evergreen MS Center; Seattle, WA  
 2000-2004 Ward and Consult Attending,  
 Puget Sound Veterans' Affairs Hospital Medical Center (U of W); Seattle, WA

### **Other Teaching Experience:**

03 Nov 2021 DDx of transverse myelitis; morning report for Stanford Neurology housestaff  
 20 Oct 2021 Diseases of the spinal cord. Stanford Neurology residency didactics; CAM  
 13 Oct 2021 Disease modifying therapies in MS. Stanford Neurology residency didactics; CAM  
 08 Feb 2021 Professors' Rounds, morning report for Stanford housestaff: virtual  
 4 Apr 2020 Department of Neurology Teleneurology Examination teaching session,  
 in conjunction with Stanford Teleneurology Resident Working Group  
 12 Oct 2018 Course Director, *Bridging Breakthroughs in Neuroscience from Bench to Bedside*:  
 Stanford Center for Continuing Medical Education. Li Ka Shing Center;  
 13 Jan 2017 HHD223 "CNS Demyelinating Diseases;" Stanford SOM: taped lectern lecture  
 11 Jan 2016 HHD223 Health & Human Disease Lecture; Stanford School of Medicine  
 01 Apr 2015 Q6 Neurology Lecture and Workshop; LK130: Stanford School of Medicine

31 Jan 2014 HHD223: Demyelinating Diseases. Lecture with test questions; Stanford SOM  
30 Jan 2014 INDE 205: Advanced Clinical Skills Neurology Examination; Stanford SOM  
08/14/13 PCAP Neuroscience Symposium 2013: DDx Muscle Weakness; Stanford SOM  
1/31/13 INDE 205: Advanced Clinical Skills; Stanford University School of Medicine  
1/28/13 HHD223 Health & Human Disease, Brain Block; with test questions: Stanford  
University School of Medicine  
1/24/13 INDE 205: Advanced Clinical Skills; Stanford University School of Medicine  
2012-present Founder, Clinical Neuroimmunology Case Conference Monday noon series  
Department of Neurology and Neuroscience, Stanford University; Stanford, CA  
2008-present Division coordinator, MS-Clinical Neuroimmunology resident didactic series;  
Last series 27 April-25 2016: Clinical Neuroimmunology;  
Neurology and Neurosciences; Stanford University; Stanford, CA  
2008-present Preceptor, MS and Clinical Neuroimmunology elective for housestaff  
Department of Neurology and Neurosciences; Stanford University; Stanford, CA

**Fellows/Clinical Neuroimmunology: (year of fellowship training: present position)**

2021-2023 Neda Sattarnezhad, MD  
Sylvia Lawry Fellowship in Multiple Sclerosis & Clinical Neuroimmunology;  
Department of Neurology & Neurosciences; Stanford University; Stanford, CA  
2020-2022 Jamie McDonald, MD  
Sylvia Lawry Fellowship in Multiple Sclerosis & Clinical Neuroimmunology;  
Department of Neurology & Neurosciences; Stanford University; Stanford, CA  
2019-2021 Elaine Su, MD  
Sylvia Lawry Fellowship in Multiple Sclerosis & Clinical Neuroimmunology;  
Clinical Assistant Professor in MS-Neuroimmunology, UCLA Medical Center;  
Los Angeles, CA: 2021-present  
2018-2020 Nina Bozinov, MD  
Sylvia Lawry Fellowship in Multiple Sclerosis & Clinical Neuroimmunology;  
Director, Kootenai Multiple Sclerosis Center; Coeur d'Alene, Idaho: 2020- pres  
2017-2018 Aaron Carlson, MD  
University of Colorado Hospital Authority; Aurora, CO: 2019-present  
2016-2017 Luka Vlahovic, MD  
Clinical Assistant Professor, Multiple Sclerosis Clinic. Department of Neurology;  
Creighton University Medical Center; Omaha, NE: 2017-present  
2015-2016 Lucas Kipp, MD  
Clinical Assistant Professor, Fellowship Director, Division Education Chief;  
Stanford University Multiple Sclerosis Center and Neuroimmunology Clinic;  
Palo Alto, CA  
2014-2015 Esther Melamed, MD, PhD  
Assistant Professor of Neurology & Neuroimmunology; Dept. of Neurology;  
Founder, MS Clinic Dell Seton Medical Center; Austin, TX: 2015-  
2012-2013 Alexandra Goodyear, MD, MS  
Sylvia Lawry Fellowship in Multiple Sclerosis & Clinical Neuroimmunology;

Global Development Lead, Genentech: South San Francisco, CA

### **Hospital or Affiliated Administration and Committee Assignments:**

- 2008-present Chief, Division of Neuroimmunology,  
Department of Neurology & Neurosciences; Stanford University; Stanford, CA
- 2020-present. Member, Institute for Immunity, Transplantation & Infection; Stanford, CA
- 2008-2019 Neurology Clerkship Director,  
Department of Neurology and Neurosciences; Stanford University; Stanford, CA
- 2009-2019 Education Committee Member,  
Department of Neurology & Neurosciences; Stanford University; Stanford, CA
- 2008-present Residency Ranking and Selection Committee; Department of Neurology;  
Stanford University; Stanford, CA
- 2016-2018 Course Director, *Breakthroughs in Neurologic Therapies* Annual Symposium;  
Departments of Neurology & Neurosurgery; San Francisco, CA
- 2010-2018 Fellowship Director, Clinical Neuroimmunology Fellowship Program;  
Stanford University Department of Neurology and Neurosciences; Stanford, CA
- 2009-2011 Steering Committee, Criterion Based Evaluation Initiative;  
Stanford University School of Medicine; Stanford, CA

### **National Committee Memberships:**

- 2018-2020 Chair, Multiple Sclerosis Section, American Academy of Neurology;  
St. Paul, MN: by national-international member election
- 2018-present Member, National Medical Advisory Council National Multiple Sclerosis  
Society; New York, NY
- 2020-2022. Member, John J. Dystel Award Committee; American Academy of Neurology
- 2015-present Member, Association for University Professors of Neurology (AUPN); #680
- 2014-2016 Vice Chair, Multiple Sclerosis Section, American Academy of Neurology  
peer-elected from national membership; American Academy of Neurology
- 2014-2015 AAN MS and CNS Inflammatory Disease Topic Work Group TWG; AAN
- 2011-2014 Chair, MS Education Workgroup, Multiple Sclerosis General Section  
American Academy of Neurology; St. Paul, MN
- 2013-2014 ACP Clinical Effectiveness Study Network OPT-UP Members
- 2010-2014 Executive Committee, MS General Section Councilor  
American Academy of Neurology; peer elected 2010
- 2011-2013 ACP Repository Oversight Committee  
Accelerated Cure Project for MS; Waltham, MA
- 2008-2011 Member, American Academy of Neurology MS Education Task Force
- 2008-present Member, National Consortium of Multiple Sclerosis Centers (CMSC)

### **Other Professional Positions held:**

2020-present Member, Stanford Institute for Immunity, Transplantation and Infection;  
Stanford University, Stanford, CA

2019-present Affiliated Faculty,  
Wu Tsai Neurosciences Institute; Stanford University, Stanford, CA

2013-present Clinical Professor of Neurology,  
Department of Neurology & Neurosciences; Stanford University; Stanford, CA

2008-2013 Clinical Associate Professor of Neurology,  
Department of Neurology and Neurosciences; Stanford University; Stanford, CA

2004-2008 Founder and Chief Medical Officer,  
MS Hub Medical Group and Evergreen MS Center; Seattle/Kirkland, WA

1996-2004 Founder and Medical Co-Director,  
Overlake Multiple Sclerosis Clinic; Bellevue, WA

1993-2004 Attending Neurologist with Special Interest in Clinical Neuroimmunology,  
Neurological Associates of WA; Bellevue/Kirkland, WA

### Professional Society Memberships:

2016-present Member, Stanford Medicine Teaching and Mentoring Academy

2008-present Fellow, American Academy of Neurology

2009-present Member, Association of University Professors of Neurology (AUPN)

2006-present MS Section; American Academy of Neurology

2004-present Member, Consortium of Multiple Sclerosis Centers

2008-present Member, San Francisco Neurological Society

2008-2016 Member, Pan-Asian Committee for Treatment and Research in MS

2016-present Member, California Neurology Society; Sacramento, CA

### Editorial Boards:

2013-2017 Reviewer, *Multiple Sclerosis Journal* (impact factor 4.472; 25/191 in Neurology)

2011-2013 *Journal of Neurological Sciences*

2008-2013 Ad-hoc Reviewer, *Continuum: Lifelong Learning in Neurology*

### Peer Reviewed Publications:

ORCID id identifier: <http://orcid.org/0000-0002-1721-6081>

- The B Cell Repertoire in Multiple Sclerosis Reveals Molecular Mimicry between EBV EBNA1 and GlialCAM. Tobias V. Lanz, R. Camille Brewer, Peggy P. Ho, Kevin M. Jude, Daniel Fernandez, Ricardo A. Fernandes, Alejandro Gomez, Gabriel Nadj, Ryan D. Schubert, Bianca Teegen, **Jeffrey E. Dunn**, Christopher B. Lock, Lucas B. Kipp, Victoria C. Cotham, Beatrix M. Ueberheide, Blake T. Aftab, Michael R. Wilson, Rachael J.M. Bashford-Rogers,

Michael Platten, Raymond A. Sobel, Christopher K. Garcia, Lawrence Steinman, William H. Robinson. 2021-06-09836C. *Nature* 10 Mar 2022

- Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology. Le H. Hua, Ahmed Obeidat, Lilyana Amezcua, Jeffrey A. Cohen, Kathleen Costello, **Jeffrey Dunn**, Jeffrey Gelfand, Myla Goldman, Sarah Hopkins, Douglas Jeffery, Stephen Krieger, Scott Newsome, Suma Shah, Nancy Sicotte, Vijayshree Yadav, Erin Longbrake. *Neurology Clinical Practice* August 2021; 11; (4): 352-357: doi: 10.1212.CPJ.000000000000104
- Human KIR+ CD8+ T cells target pathogenic T cells in celiac disease and are active in other types of autoimmunity. Li, J., Zaslavsky, M., Sikora, M., Christophersen, A., Chiou, SH, Chen, L., Ji, X., Willhemy, J., McSween, A., Van Unen, V., Palanski, B., Bhamidpati, K., Pai, J., Kipp, L., **Dunn, J.**, Hauser, S., Oksenberg, J., Satpathy, A., Robinson, W., Steinmetz, L., Khosla, C., Nadea, K., Utz, PJ, Sollid, L., Fernandez-Baker, N., Saligrama, N., Davis, M. Submitted to *Science*
- Defining the Neuroimmunology/Multiple Sclerosis Subspecialty: Surveys of Fellowship Training in the United States. Longbrake, E., Obeidat, A., **Dunn, J.**, Sicotte, N., Hua, L. Lippincott Williams & Wilkins 2020. Web of Science # 000536058001053
- Advocacy, Dissemination and Implementation Strategies for an International Standardized MRI Protocol for Diagnosis and Follow-Up of patients with Multiple Sclerosis. Saslow, L., Li, D., Halper, J., Banwell, B., Barkhof, F., Barlow, L., Costello, K., Damiri, B., **Dunn, J.**, Giri, S., Maes, M., Morrow, S., Newsome, S., Oh, J., Friedemann, P., Quarterman, P., Reich, D., Shewchuk, J., Shinohara, R., Van Hecke, W., Van der Ven, K., Wallin, M., Wolinsky, J., Traboulsee, T. *Int J MS Care*. 2020; 22:226-232.
- Repopulation of T, B and NK cells following alemtuzumab treatment in relapsing-remitting Multiple Sclerosis. Gilmore, W., Lund, B., Li, P., Levy, A., Kelland, E., Akbari, O., Groshen, S., Yong, S., Pelletier, D., Weiner, L., Javed, A., **Dunn, J.**, Traboulsee, T. *Journal of Neuroinflammation* 2020; 17 (1): 189
- Current State and Frontiers in the Treatment of Multiple Sclerosis: Report of an Expert Meeting. Hartung, H-P, Berger, J., Berkovich, R., **Dunn, J.**, Gass, A., Haas, J., Katri, B., Kleinschnitz C., Tackenberg, B., Weinstock-Guttman, B., Wiedndl, H., Zamvil, S., Zimssen, T., Gold, R. *Therapeutic Advances in Neurologic Disorders (SAGE)* 2019
- The North American Registry for Care and Research in Multiple Sclerosis. Rammohan, KW, Li, D., Halper, J., Murphy, S., Patton, L., Berger, J., Carlson, A., China, A., Cohan, S., Cross, A., **Dunn, J.**, Fox, E., Gupta, A., Kamin, S., Mao-Draayer, Y., Mayer, L., Repovic, P., Ruiz, J., Rus, H., et al. *Sage Publications LTD*. 2019: 79-80
- Autoimmune Hepatitis During Treatment of Multiple Sclerosis with Alemtuzumab. A Carlson, N Bozinov, L Kipp, **J Dunn**, C Lock. *Neurology* April 9, 2018 vol. 90 no 15 supplement P5.350.
- Infectious Complications of Multiple Sclerosis Therapies: Implications for screening, prophylaxis, and management. Epstein, D.J., **Dunn, J.**, Deresinski, S. *Open Forum Infectious Diseases* S.2018; 5 (8) ofy17
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. Hauser S., et al., **OPERA II Clinical Investigators**. *New England Journal of Medicine* 19 Jan 2017; 376; 3: 221-234

- Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Giovannoni G., et al., **CARE-MS II Investigators**. *Neurology* 2016; 87: 1985-1992
- Interferon beta treatment requires B-cells for efficacy in neuro-autoimmunity. Schubert R., Hu Y., Kumar G., Szeto S., Abraham P., Winder, J., Guthridge JM, Pardo G., **Dunn J.**, Steinman L., Axtell R.C. *Journal of Immunology*, 2015; 194 (5): 2110-2116
- Disease Modifying Therapies for non-relapsing Multiple Sclerosis: Absence of evidence does not constitute evidence of absence. **Dunn, J.** *Neurol Clin Pract.* December 2013; 3 (6): 515-518
- Mobility Concerns in Multiple Sclerosis- Studies and Surveys on US patient populations of relevance to nurses. Lee, J., **Dunn J.** *US Neurology*; 2013; 9(1): 17-23
- Lublin, F. et al. and **CombiRx Investigators**. Randomized study combining interferon and glatiramer acetate in Multiple Sclerosis. *Ann Neurol* 2013 Mar; 73 (3): 327-340
- The CombiRx Trial of Combined Therapy with interferon and glatiramer acetate in relapsing remitting Multiple Sclerosis: design and baseline characteristics. Lindsey, J. et al. and **CombiRx Investigators**. *Mult Scler Relat Disord.* 2012 April 1; 1 (2): 81-86
- Alemtuzumab for patients with relapsing Multiple Sclerosis after disease-modifying therapy: a randomized controlled Phase 3 trial. Coles AJ, et al. **CARE MS II Investigators**. *Lancet* 2012; 380: 1829-1839
- Peripheral Blood Immune Cell Profiling Reveals Distinct Immunological and Clinical Phenotypes in Neuromyelitis Optica. You, Y., Alonso, M., Axtell, R., Kurnellas M., Lebus D., Goodyear A., **Dunn J.**, Steinman L., Engleman E., Fire A., Boyd S., Han M.; in submission
- Protective effect of elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Herges K, deJong BA, Kolkowitz I, Dunn C, Mandelbaum G, Ro RM, Maini A, Han, MH, Killestein J. Polman C, Goodyear A, **Dunn J**, Steinman L, Axtell RC; *Multiple Sclerosis* 2012; 18 (4): 398-408
- Dalfampridine: A Brief Review of Its Mechanism of Action and Efficacy as a Treatment to Improve Walking in Patients With Multiple Sclerosis; **Dunn J.**, Blight D. *Curr Med Res Opin.* 2011 Jul;27(7):1415-23
- The impact of mobility impairment on the burden of caregiving in individuals with Multiple Sclerosis. **Dunn J.** *Expert Rev Pharmacoecon Outcomes Res:* 2010 Aug; 10 (4) 433-440
- CMV Optic Neuritis with extensive tracking along the visual pathway: Pershing S, **Dunn J.**, Khan A, Liao YJ; *J Neuroophthalmology* 2009; 29 (3):223-226
- Glatiramer acetate after induction therapy with mitoxantrone in relapsing Multiple Sclerosis: Vollmer, T., Panitch, H., Bar-Or, A., **Dunn, J.**, Freedman, M., Gazda, S.K., Campagnolo, D., Deutsch, F. and Arnold, D.: *Multiple Sclerosis* 2008; 14: 663-670
- Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS; Arnold, D.L., Campagnolo, D., Panitch, H., Bar-Or, A., **Dunn J.**, Freedman, M.S., Gazda, S.K., Vollmer, T: *J Neurol* 2008; 255: 1473-1478
- Tovaxin for early relapsing Multiple Sclerosis Phase 2b placebo controlled trial of autologous T-cell vaccination in patients with Clinically Isolated Syndrome or relapsing remitting MS: Fox, EJ and The **TERMS Study Investigators**: *Multiple Sclerosis* 2008;14: S5-S27
- A randomized, double blind, dose comparison study of Glatiramer Acetate in relapsing remitting Multiple Sclerosis; J.A. Cohen, M. Rovaris et al and the **9006 Study Group**: *Neurology* 2007 Mar 20; 68 (12):939-944

- Results of a randomized, double blind, parallel group study assessing safety and efficacy of 40 mg vs. 20 mg of Glatiramer Acetate on MRI measured disease activity in relapsing remitting Multiple Sclerosis; J.A. Cohen, M. Rovaris, et al and the **9006 Study Group**; *Neurology* 2006; 67: 185
- Gingko Biloba in the treatment of Alzheimer's Disease; **Dunn, J.**, Maidan, R. and Pallis, J.; *Alternative Medicine*; December 1998: Volume I, Issue 15; 1-2
- Atherosclerotic Aortic Disease as a source of embolic infarct; Bursell, John P., Odderson, I. and **Dunn, J.**; *Journal of Neurovascular Disease* 1996; 1; 2: 35-38
- Intracerebral Bacillary Angiomatosis in a patient infected with HIV; Spach, D., Panther, L., Thorning, D., **Dunn, J.** Florde, J.L., Miller, R.; *Annals of Internal Medicine*; 1992: 116; 740-743

### Abstracts: & posters:

- Invited platform and poster presentation: Adaptive B cell and T cell responses to CoV-2 vaccination in patients with Multiple Sclerosis on disease modifying immunotherapy. Tomczak, A., Sumera, J., Joseph, Y., Wu, D., McDonald, J., Sattarnezhad, N., Kipp, L., Lock, C., Hay, M., and **Dunn, J.** : ACTRIMS. 22 Feb 2022. West Palm Beach, Florida
- New onset headache in neurosarcoidosis: An early sign of leptomeningeal involvement. Wu, D., Tomczak, A., Sattarnezhad, N., McDonald, J., Sumera, J., Kipp, L., Lock, C., **Dunn, J.**, Han, M. : ACTRIMS: 23 Feb 2022. West Palm Beach, Florida:
- ACTonMS Virtual Think Tank White Paper: 3 Complementary Transitions in Patient Care Inspired by Health Care Innovations in Response to the Pandemic. Cleveland Clinic Foundation **National Expert panel**. 2021
- MS Treatment Guidelines during the Coronavirus pandemic. Miller, A., **Dunn, J.**, Costello, K. and NMAC, National Multiple Sclerosis Society; 2020
- The North American Registry for Care and Research in Multiple Sclerosis. Kottil Rammohan, David Li, June Halper, Sara McCurdy Murphy, Lisa Patton, Joseph Berger, Aaron Carlson, Angel China, Stanley Cohan, Anne Cross, **Jeffrey Dunn**, Edward Fox, Ajay Gupta, Stephen Kamin, Yang Mao-Draayer, Lori Mayer, Pavle Repovic, Jennifer Ruiz, Horea Rus, Rohini Samudralwar, Adnan Subei, Florian Thomas: ACTRIMS; 01 March 2019: Dallas, Texas
- Systems approaches to discovering T cell antigen (s) in neurological diseases [poster and oral presentation]. N Saligrama, F Zhao, MJ Sikora, WS Serratelli, RA Fernandes, DM Louis, W Yao, X Ji, J Idoyaga, VB Mahajan, LM Steinmetz, Y Chien, SL Hauser, JR Oksenberg, LB Kipp, **J Dunn**, CK Garcia, MM Davis. Presented at Gordon Research Conference, 2019 Neuroimmune Communication in Health and Disease, Ventura, CA. January 13, 2019 – January 18, 2019
- Autoimmune Hepatitis During Treatment of Multiple Sclerosis with Alemtuzumab. Carlson A., Kipp L., Charville G., Sherman C., **Dunn, J.**, Lock C. American Academy of Neurology Annual Meeting; abstract # 1069; position 350. Los Angeles, CA: 26 April 2018



- Positive GAD-65 antibodies in patients with autonomic dysfunction. L Vlahovic, L Kipp, **J Dunn**, L Nguyen, S Jaradeh. 28<sup>th</sup> International Symposium on the Autonomic Nervous System; 2017 Nov 1-4; Clearwater Beach, Florida, USA.
- Leukocyte repopulation following alemtuzumab treatment in relapsing-remitting Multiple Sclerosis contains multiple regulatory immune cell types. Lund B., Traboulsee A., Javed A., **Dunn J.**, Weiner L., Li P., Kelland E., Levy A., Gilmore W. P979. Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ECTRIMS); Paris, France: 25-28 October 2017
- Positive GAD-65 antibodies in patients with autonomic dysfunction; Vlahovic L., Kipp, L., **Dunn, J.**, Nguyen L., Jaradeh, S. 2017
- Assessment and Management Strategies for Relapsing Multiple Sclerosis Patients with Breakthrough Disease and Suboptimal Treatment Response; **Dunn J.**; Clin-Topics; January 2017; FCH-US-2262; pages 1-6
- Alemtuzumab Significantly Improves Disability in Patients with Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy as Assessed Using a Novel, Composite Measure of Confirmed Disability Improvement: Results from CARE-MS II; Singer B., **Dunn J.**, Izquierdo G., Thangavelu K., Mittal A., Pozzilli C., on behalf of MS-CARE II Investigators; 32<sup>nd</sup> Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); London, England, UK: 14-17 Sept 2018
- T cell-driven dimethyl fumarate induced lymphopenia in patients with Multiple Sclerosis; Lee J-M, Lock, C., Ho, P and **Dunn J.**; Consortium of Multiple Sclerosis Centers annual meeting; National Harbor, Maryland: 2 June 2016
- T cell-driven dimethyl fumarate induced lymphopenia in patients with MS; Lee, J-M, and **Dunn, J.E.**; PACTRIMS; 20 Nov 2015: Seoul, South Korea
- Characteristics of leukocyte recovery following treatment with humanized anti-CD52 (alemtuzumab/Lemtrada) in multiple sclerosis W. Gilmore, B.T. Lund, A. Traboulsee, A. Javed, **J.E. Dunn**, L.P. Weiner, P. Li, E.E. Kelland, A.M. Levy; ECTRIMS; 9 October 2015: Barcelona, Spain
- The Utility of Magnetic Resonance Imaging in Multiple Sclerosis; **Dunn, J.**; PACTRIMS Pan-Asian Committee for Treatment and Research in Multiple Sclerosis; 7 Nov 2014: Taipei, Taiwan
- Discovery of a novel peripheral blood B cell signature of interferon beta therapy in MS: Schubert R.D., Abraham P., Goodyear A., Steinman L., Senior authors: **Dunn J.**, Axtell R.; Stanford University School of Medicine Neuroscience Forum; Stanford, CA: 7 June 2013
- Analysis of B Cell Subsets in Multiple Sclerosis Patients on Immunomodulatory Therapy Reveals Modulation of CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> Cells With Implications for the Diagnosis and Monitoring of MS. Schubert R., Goodyear A., Abraham P., Dunn C., Steinman L.; Senior authors: **Dunn J.** and Axtell R.; American Academy of Neurology Annual meeting abstract # P03.224; San Diego, CA: 19 March 2013
- MRI Characteristics of CNS Demyelinating Disease in Ethnic Indian Patients; Hua, Le H., Lee, Jong-mi, **Dunn J.**; Consortium of Multiple Sclerosis Centers CMSC Annual Conference; Montreal, Canada: 2011

- MRI Characteristics of CNS Demyelinating Disease in those of Indian Ethnicity; Hua L., Lee J. and **Dunn J.**; Stanford University School of Medicine Neuroscience Forum; Stanford, CA; 13 May 2011
- Clinical Trials in Multiple Sclerosis, developments and challenges: **CHOICE Study**  
**Investigators:** ECTRIMS September 2007; Prague, Czech Republic
- The Modified Rankin Score as a measure of self report in MS using baseline assessments; Colfield S. and the **CombiRx Investigator Group**; ECTRIMS 2007; Prague, Czechoslovakia
- Daclizumab in patients with active relapsing Multiple Sclerosis on concurrent interferon beta therapy Week 24 data Phase II; Montalban X, Kaufman M, Wynn D et the **CHOICE Study**  
**Investigators:** ECTRIMS October 2007; S18
- Analyzing relapse assessment in CombiRx; Cutter et al, **CombiRx Investigator Group**;  
ECTRIMS 2007; Prague, Czechoslovakia
- Mitoxantrone as induction followed by Glatiramer Acetate compared to Glatiramer Acetate monotherapy in relapsing Multiple Sclerosis; Vollmer, T., Panitch, H., Bar-Or, A., **Dunn, J.**, Freedman, M., Gazda, S.K., Campognolo, D. and Arnold, D.; ECTRIMS 2006; Madrid, Spain
- Safety and tolerability of Glatiramer Acetate in pediatric patients with relapsing remitting Multiple Sclerosis; Krupp, L., Banwell, B., Picone, M., **Dunn, J.**, Weinstock-Guttman, B., and Pardo, L.: ECTRIMS 2005; Thesalonikki, Greece
- Comprehensive outpatient management of patients with Multiple Sclerosis;  
Odderson, I.R., and **Dunn, J.**; RIMS MS Symposium; May 2001; 7<sup>th</sup> Annual RIMS Conference: Copenhagen, Denmark; May 2001
- Novantrone in the treatment of Multiple Sclerosis;  
**Dunn, J.**, Kita, M. Lucas, S., Bowen, J. and the Pacific Northwest Alliance of MS Centers;  
*Alliance News*; Fall 2001; 1-3
- Greater Washington Chapter Clinical Advisory Committee Statement on Procarin;  
Bowen, J., **Dunn, J.**, Kraft, G.H., Ratley, G., Shilling, J., Smith, C. and Thompson, L.;  
*Health Care Connection: Fall 1999: I, Issue 1*; 1-2
- Stroke: Acute Treatment and Prevention; 17<sup>th</sup> Annual University of Washington Review Course in Physical Medicine and Rehabilitation; Odderson, I., **Dunn, J.** et al; March 1996

### **Invited faculty, platform, virtual and international oral presentations:**

Invited faculty, “Evolving Paradigms: How Epstein Barr Virus EBV infection may cause Multiple Sclerosis”; Texas Neurological Society Annual Winter Conference; 05 Feb 2022: Austin, Texas

Chairman, International Panel on the Pathophysiology of Neuromyelitis Optica Spectrum Disorders: Perspectives from USA, Canada, Australia, Germany and Japan: September 2021: virtual, international audience

Chairman, A Study and discussion of Secondary Progressive MS, Co-Chair with Aaron Boster, MD: September 2021: virtual, national audience

Chairman, “The Cascade Effect: The Role of Complement in Neuroimmunology and NMOSD”;  
*PACTRIMS International Symposium*; Singapore City, Singapore: 15 November 2019

Invited Faculty, “Multiple Sclerosis Update,” *Stanford University Department of Medicine Grand Rounds*; Stanford, CA: 06 November 2019

Keynote Speaker, “The Immunopathology of Neuromyelitis Optica Spectrum Disorder,”  
*International NMOSD Consortium*; Athens, Greece: 10 Mar 2019

Invited Faculty, *Neuroscience Beyond 2020*: “Drivers of first line treatment decisions;” Sitzung 2.  
Samstag 26 May 2018. 80538 Munchen; Munich, Germany

Invited Faculty, MS Leadership Council. 11 Nov 2017; Boston, Massachusetts

Chair and Moderator, “The Topographical Model of Multiple Sclerosis: A dynamic visualization of disease course.” *Emerging Science Journal Club Program/ECTRIMS*; 24 Oct 2017; Paris, France

Platform Faculty, “Multiple Sclerosis Update 2017;” California Neurology Society; San Francisco, CA: 27 May 2017

Platform Faculty, “NMO 101;” Stanford Medicine NMO CIRCLES Patient Day; Stanford University LKSC Center; Stanford, CA: 28 Jan 2017

Distinguished Faculty, “Immunology: A Review of the Fundamentals,” American Headache Society Annual Symposium; Scottsdale, AZ: 18 Nov 2016

Panel Chair, “Evaluating Therapeutic Success”; Dunn J., Singer P.A., Liebman, H. & Appel G.; Palo Alto, CA: 10 November 2016

Keynote Speaker, “Specialty MS Patient Care: A Symposium for Developing Clinicians”; San Francisco, CA: 26 Oct 2016

Grand Rounds Presenter, “Multiple Sclerosis Update 2016;” California Pacific Medical Center; San Francisco, CA: 28 April 2016

Platform faculty, “Making the Most out of Your Neurology Clerkship: The Stanford Experience”; Navigating Your Career, *American Academy of Neurology Annual Meeting*; Vancouver, British Columbia, Canada: 20 April 2016

Platform Faculty, “Rebounding from Chronic Disease”; Oracle Arena; Oakland, CA: 6 Apr 2016

**Sponsored Clinical Research/Clinical Trials (Active):**

Principal Investigator, Project BIG: The Brain, Immune and Gut Research Initiative to find the cause and cure of Multiple Sclerosis. 2018-present, Stanford BIG Fund

Principal Investigator, A Multicenter Randomized Controlled Trial of best available therapy versus autologous hematopoietic stem cell transplant for treatment-resistant relapsing Multiple Sclerosis. Protocol ITN077AI. Sponsor Immune Tolerance Network and the National Institute of Allergy and Infectious Disease (NIAID). ClinicalTrials.gov identifier NCT04047628. Status: site selected and approved, 2021

Co-Investigator, KIR and HLA effects in CNS paraneoplastic syndromes and related neuroimmune conditions, (E. Mignot, PI): Stanford SPO # 163059, Sponsor National Institutes of Health NIH, 2021

Principal Investigator, NARCRMS Toward the Development of a National Longitudinal Data Base in Multiple Sclerosis. Sponsor: The Consortium of Multiple Sclerosis Centers (CMSC): 08/01/2017-07/31/2022

Investigator,  
Analysis of antibodies and immune responses in demyelinating disease (in collaboration with Bill Robinson, MD, PhD): ID: IRB-34529; 2015-present

Sub-Investigator, High Dimensional Analysis of Immune Subsets with Mass Cytometry and Multiparameter Flow Cytometry in Patients with Secondary Progressive Multiple Sclerosis Treated with Siponimod (L.Steinman, PI): Stanford eProtocol #59039

Investigator,  
7T MRI Characterization of Cognitive Assessment of Multiple Sclerosis and Demyelinating Diseases; ID # IRB-30481 Stanford University: August 2017-present

Investigator,  
7T MRI Characterization of Cognitive Assessment of Multiple Sclerosis and Demyelinating Diseases; ID # IRB-30481 Stanford University: August 2017-present

### **Sponsored Clinical Research/ Clinical Trials (Past or Completed):**

Principal Investigator,  
Multicenter, randomized, double blind parallel group extension to study AC-058B202 to investigate the long term safety, tolerability, and efficacy of 10, 20 and 40 mg/day ACT-128800 (Ponesimod), an oral S1P1 receptor agonist, in patients with relapsing remitting Multiple Sclerosis; Sponsor Actelion: 19 Feb 2010-2021

Principal Investigator,

A Randomized, Double-Blind, Double Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis. Protocol WA21093/A; Sponsor Genentech-Hoffman-LaRoche: June 2012-2020

Protocol Director,

Immune Modulation by Alemtuzumab in Multiple Sclerosis (in collaboration with Wendy Gilmore, PhD; USC; Los Angeles, CA): Stanford Protocol # 16988; 10/09-2019

Protocol Director, Immunogenetics Studies in Multiple Sclerosis: Vitamin D Protocol

Protocol IRB-25223: Sponsor NIH 2016-2018

Principal Investigator,

VIDAMS: Vitamin D to ameliorate MS Trial: in collaboration with Johns Hopkins University (Study PI Ellen Mowry, MD) and NIH: 2012-2018

Protocol Director,

Lymphocyte subset analysis of dimethyl fumarate associated lymphopenia; Stanford expedited protocol # 34592: 17 July 2015- 30 June 2018

Principal Investigator;

An open label extension study of safety and tolerability of intravenous alemtuzumab (Lemtrada) in patients with relapsing-remitting Multiple Sclerosis who have relapsed on therapy; extension study of Protocol # CAMMS32400597; Sponsor Genzyme Corporation; Cambridge, MA: 01 Nov 2011-01 Nov 2014

Principal Investigator;

A Phase III Randomized, Rater and Dose Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three Times weekly Subcutaneous Interferon Beta-1a in Patients with Relapsing Remitting Multiple Sclerosis who have Relapsed on Therapy; Protocol CAMMS32400597; Sponsor Genzyme Corporation; Cambridge, MA; Stanford Protocol # 16988: 08 May 2009-07 May 2012

Protocol Director,

Understanding Participation of Racial and Ethnic Groups in Multiple Sclerosis Clinical Trials; Stanford IRB Protocol # 29294: 07 March 2014-28 Feb 2015

Principal Investigator,

Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Three Doses of ACT-128800 (Ponesimod), an Oral S1P1 Receptor Agonist, Administered for Twenty-four Weeks in Patients with Relapsing-remitting Multiple Sclerosis; Sponsor Actelion: 7 Dec 2010-6 Dec 2012

Co-Investigator,

The Neuroanatomy of Pseudobulbar Affect (in collaboration with Josef Parvizi, MD, PhD; Stanford University; Stanford, CA): Stanford Protocol # 15264; 7/09-2012

Principal Investigator,

JC Virus Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Natalizumab: The STRATIFY-2 Study. Stanford Protocol #18841; Sponsor Biogen-Idec: 14 June 2011-31 May 2012

Co-Principal Investigator and Protocol Director,

Protocol Title: A Longitudinal, Case-Control Study to Collect Medical and Epidemiological Data and Blood Samples for Research Into the Causes of Multiple Sclerosis and Selected Demyelinating Diseases; Sponsor: Accelerated Cure Project; Stanford Protocol 17667: 01 Mar 2010-July 2013

Principal Investigator;

A Multi-Center, Double Blind, Randomized Study, Comparing the Combined Use of Interferon Beta 1a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing Remitting Multiple Sclerosis; CombiRx Protocol, Sponsor NIH; Bethesda, MD; September 2005-February 2008

Principal Investigator;

A Multi-Center, Randomized, Double Blinded, Placebo Controlled Study of Subcutaneous Tovaxin in Subjects with Clinically Isolated Syndrome or Relapsing Remitting Multiple Sclerosis; The "TERMS" Study; Sponsor Opexa Therapeutics; The Woodlands, Texas; November 2006-February 2008

Sub-Investigator;

A Double Blind, Randomized Multicenter Placebo Controlled Parallel Group Study Comparing Efficacy and Safety of FTY720 (Fingolimod) Administered Orally Versus Placebo in Patients with Relapsing Remitting Multiple Sclerosis; Sponsor Novartis Pharma AG; Switzerland; October 2007-February 2008

Sub-Investigator;

Open Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients with Multiple Sclerosis who Participated in the MS-F204 Trial; Acorda Therapeutics; November 2007-February 2008

Principal Investigator;

A Phase II Randomized, Double Blinded, Placebo Controlled, Multi-Center Dose Ranging Study of Subcutaneous Daclizumab in Patients with Active Relapsing Forms of Multiple Sclerosis; Protocol DAC-1012 CHOICE Study; Sponsor PDL Biopharma; October 2005-November 2007

Sub-Investigator;

Phase I, Double Blind Placebo Controlled, Dose Escalation Study of the Safety of RTL1000 in Subjects with Relapsing Remitting Multiple Sclerosis or Secondary Progressive Multiple Sclerosis; Sponsor Artielle Immunotherapeutics, Inc.; Tigard, Oregon; May 2007-February 2008

Principal Investigator;

A Multi-Center, Randomized, Double Blind, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of 40 mg Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis Patients; Protocol # 9006; Sponsor Teva Neuroscience; 7/04-11/05

Principal Investigator;

A Multi-Center, Randomized Double Blind Parallel Group Study to Evaluate the Safety and Tolerability of Natalizumab in Subjects with Multiple Sclerosis Who Have Completed Studies C-1801, C-1802 and C-1803; Protocol # C-1808; Sponsor Biogen-Idec; Cambridge, MA; 7/04-10/05

Principal Investigator;

A Multi-Centered Two Arm, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Induction Treatment with Mitoxantrone (Novantrone) Preceding Treatment with Glatiramer Acetate versus Chronic Treatment with Glatiramer Acetate Alone in Relapsing Forms of Multiple Sclerosis; Protocol #NC-100; Sponsor Teva Neuroscience; North Wales, PA; 8/04-2/06

Principal Investigator;

A Retrospective Study to Evaluate the Safety and Tolerability of Copaxone for Injection in Pediatric patients with Relapsing Remitting Multiple Sclerosis; Protocol # PM012; Sponsor Teva Neuroscience; North Wales, PA; 8/04-3/05

Sub-Investigator;

A Double Blind, Placebo Controlled 13 Week Parallel Group Study to Evaluate the Efficacy, Safety and Activity of Oral Fampridine-SR in Subjects with Multiple Sclerosis; Protocol # MS-F301; Sponsor Acorda Therapeutics; Hawthorne, NY; 6/04-2/08

Principal Investigator;

A Phase IV Study of Copolymer I in the Treatment of Multiple Sclerosis; Protocol Cop-I; Sponsor Teva Marion Partners; Kansas City, MO; 1994-1996

## **Inventions and Intellectual Property:**

Inventor, "Marker for determination of patient responsiveness;" **Dunn, J.**, Axtell R., Schubert R.

Developed a test that measures transitional B cells in peripheral blood for use in determining patient responsiveness to Multiple Sclerosis (MS) treatments.  
United States Patent & Trademark Office patent # 10054588; issue date 21 Aug 2018

### Special Materials:

Moderator, “Candid Conversations, real world insights on Relapsing Multiple Sclerosis;” **Dunn J.**, Cabot A., O’Connell B., Katz, J. : filmed in Brooklyn, NY: 2016. Real-Tec

Commentator, Everydayhealth.com

Does Obesity Raise the risk of Multiple Sclerosis?

<http://www.everydayhealth.com/multiple-sclerosis/obesity-raise-risk-multiple-sclerosis>: 11 Jan 2016

Expert Faculty, Pan-European Union Broadcast: “Dimethyl Fumarate for Relapsing Remitting Multiple Sclerosis;” media broadcast to 14 member countries of the EU; HBO Studios; New York, New York: 12 March 2014

Expert Faculty, Visiting Professor CME: Peer-to-Peer Academic Updates, Multiple Sclerosis Year in Review; national webcam, PRIME Education Inc., Tamarac, FL: 11/12-01/13

Multiple Sclerosis Residency Core Curriculum; **Dunn J.**, Vokaty W. Lisak R. and the American Academy of Neurology MS Education Task Force; 2012-2013  
<http://www.aan.com/go/about/sections/curriculaMS> Section

MS On The Rise: *CBS Evening News*; [cbsnews.com/](http://cbsnews.com/) Up To The Minute/ MS: April 2007

### Post-degree Honors and Awards:

- 2021 Oscar Salvatierra Award for Exceptional Service to Medical Students and the School of Medicine: Stanford University School of Medicine
- 2021 Castle Connolly “Top Doctor” for 10+ years, & featured in *San Francisco Magazine*: <https://www.castleconnolly.com/top-doctors/jeffrey-e-dunn-neurology-101cc000527>
- 2020 Neurology Clerkship Teaching Award; Stanford University Dept. of Neurology
- 2020 Top Neurologist; *California Magazine*
- 2019 A. B. Baker National Teacher Recognition Award for contributions to improving Neurology through commitment to education; American Academy of Neurology
- 2019 MS Healthcare Partner of the Year: National MS Society, Nor-Cal Chapter
- 2018 Likelihood to Recommend Award: physician with LTR scores above the 90<sup>th</sup> percentile ranked nationally; Stanford Health Care; Stanford, CA
- 2017 Arthur L. Bloomfield Award in Recognition of Excellence in the Teaching of Clinical Medicine; Stanford University School of Medicine



- 2017-2020 Best Doctors, *US News & World Report* Health Care Rankings
- 2016-2017 Neurology Clerkship Student Teaching Award; Stanford University
- 2016 Special Commendation, California State Senate, “in recognition of commitment and dedication to providing outstanding care for your patients, your leadership and efforts with cutting edge MS research and your ongoing contributions to the MS community.” Senator Lois Wolk, 3<sup>rd</sup> district. 30 July 2016
- 2015-2016 Neurology Clerkship Student Teaching Award; Stanford University
- 2014-2015 Neurology Clerkship Student Teaching Award; Stanford University
- 2013-2014 Neurology Clerkship Student Teaching Award; Stanford University
- 2014-2020 America’s Top Physicians; Consumers’ Research Council of America
- 2013-2014 Neurology Clerkship Student Teaching Award; Stanford University
- 2012-2013 Neurology Clerkship Student Teaching Award; Stanford University
- 2013 Henry J. Kaiser Family Foundation Award for Excellence in Clinical Teaching; Stanford University School of Medicine
- 2012-2013 Excellence in Teaching Award, Stanford University School of Medicine
- 2012-2013 AUPN Recruitment Award for Neurology Clerkship among US medical schools
- 2012-2013 Top Doctors; US News & World Report National Rankings
- 2011-2012 Excellence in Teaching Award, Stanford University School of Medicine
- 2011-2012 Neurology Clerkship Student Teaching Award; Stanford University
- 2012, 2013 America’s Top Physicians; Consumers’ Research Council of America
- 2011 Arthur L. Bloomfield Award in Recognition of Excellence in the Teaching of Clinical Medicine; Stanford University School of Medicine
- 2011 Association of University Professors of Neurology AUPN Recruitment Award, highest percentage of graduating medical students proceeding to postgraduate training in the clinical neurosciences; Stanford University School of Medicine
- 2010-2011 Neurology Clerkship Student Teaching Award; Stanford University
- 2009-2010 Excellence in teaching Award, Stanford University School of Medicine
- 2009-2010 Neurology Clerkship Student Teaching Award; Stanford University
- \* 2010 Guide to America’s Top Physicians; Consumers’ Research Council of America
- 2008-2009 Lysia Forno Award for Teaching Excellence to Neurology housestaff
- 2008-2009 Neurology Clerkship Student Teaching Award; Stanford University
- 1998-2007 America’s Top Rated Physicians, *Guide to Top Doctors*: 1998-2007 inclusive
- 2005 Finalist, Pacific Northwest Writers’ Association for best screenplay
- 2004 Seattle’s Top Doctors for Women, *Seattle Magazine*
- 1996 Subject of biographical inclusion, *Who’s Who in America*

## Philanthropy and Community Service:

Orphan Outreach,

Charitable medical care to children orphaned by the African AIDS crisis: Mathare slums outside Nairobi, Kenya; and Bungoma, Kenya: July 2017: [www.orphanoutreach.org](http://www.orphanoutreach.org)

Buck/Cardinal Club, Stanford University

To help Stanford Athletics field 36 top-level varsity sports teams and support student athletes; Stanford University Department of Athletics; Stanford, CA: 2013-present

Charter Hill Society, UC Berkeley

For extraordinary commitment to preserving and enhancing excellence in education; UC Berkeley; Berkeley, CA: 2011-2015